About US
Contact us
-
Hey, pharma, you're not spending enough on advertising, one expert saysThink pharma spends too much on advertising? Think again, says one expert. Drugmakers need to spread more money into digital channels just to keep up with consumers' growing exposure to ads, says Gayl2016/3/22
-
J&J's Stelara, playing defense in psoriasis, posts more positive Crohn's dataJohnson and Johnson's ($JNJ)Stelarais facing fierce new competition in the psoriasis arena. But the New Jersey drugmaker is looking for ways the med can make its mark in other disease areas, and it's2016/3/21
-
Senators lambaste Turing for 'unethical' price hikes at latest drug price hearingTuring Pharmaceuticalswas front and center again at a recent Senate hearing over drug price increases, and for the most part, it was the same old song and dance. The drugmaker came under fire by a bip2016/3/21
-
EU approves €10m funds for research on Zika virusThe European Commission is providing €10m in funding to support research on the Zika virus, which is currently found to be active in several parts of Latin America. In November last year, preliminary2016/3/18
-
Pharmapack 2016: Green Pharmaceutical PackagingGerresheimer has released the first eco-friendly plastic containers for pharmaceutical and cosmetic applications, BioPack. It makes an excellent substitute for traditional PE and PET because it has t2016/3/18
-
Takeda, Frazier Healthcare form new company to develop urology and gynaecology therapeuticsTakeda Pharmaceutical and Frazier Healthcare Partners have set up a new biopharmaceutical company to develop new therapeutics in urology and gynaecology. Known as Outpost Medicine, the new company ha2016/3/17
-
Pfizer's Xalkori receives FDA approval to treat ROS1-positive metastatic non-small cell lung cancerPfizer has received approval from the US Food and Drug Administration (FDA) for a supplemental new drug application (sNDA) for Xalkori (crizotinib) to treat patients with ROS1-positive metastatic non-2016/3/17
-
European Medicines Agency to start review of Gilead’s cancer medicine ZydeligThe European Commission has requested the European Medicines Agency (EMA) to start a review of Gilead Science's cancer medicine Zydelig (idelalisib), following concerns over serious adverse events in2016/3/16
-
India’s Lupin completes $880m acquisition of US firm GavisIndian drugmaker Lupin has completed the acquisition of US-based Gavis Pharmaceuticals and Novel Laboratories (Gavis) in a previously announced deal worth $880m. The move comes on the heels of Lupin2016/3/16
-
Pfizer wins stay from Indian court after regulator bans popular cough syrupsWestern drugmakers often complain about what sometimes seems like the capricious nature of Indian drug regulation. Now Pfizer ($PFE) has asked an Indian court to get involved after a regulator include2016/3/15